Li Qin, Zhang RuiXue, Yan Han, Zhao PengFei, Wu Li, Wang Hui, Li Teng, Cao Bangwei
Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Department of Internal Medicine, The First Hospital, Tsinghua University, Beijing 100016, China.
Oncotarget. 2017 May 18;8(40):67140-67151. doi: 10.18632/oncotarget.18007. eCollection 2017 Sep 15.
Human epidermal growth factor receptor 3 (HER3) is closely involved in tumor progression and is an important target of therapy. To evaluate the prognostic significance of HER3 in malignant solid tumors, we searched the PUBMED, EMBASE and CNKI databases for relevant studies written in English or Chinese up to December 2015. Fifteen studies comprising 2964 patients were identified. The HER3 rate ranged from 9.0-75.1 % in malignant solid tumors: 30.3-75.1 % in breast cancers, 51.1-74.5 % in colorectal cancers, 13.7-59.0 % in gastric cancers, and 54.5-74.4 % in cervical cancers. For patients with a malignant solid tumor, the death risk was higher for those with a HER3 tumor than for those with a HER3 tumor (HR 1.60, 95% CI: 1.27 - 2.02, < 0.001). Subgroup analysis revealed this was also the case for patients with digestive or gastric cancer (HR 1.78, < 0.001; HR 2.18, < 0.001). By contrast, HER3 had no prognostic significance in colorectal or breast cancer (HR 1.52, = 0.296; HR 1.23, = 0.108). HER3 is thus associated with poor survival in overall and in gastric cancer. The prognostic significance of HER3 in other tumors is uncertain and deserves further study.
人表皮生长因子受体3（HER3）与肿瘤进展密切相关，是一个重要的治疗靶点。为评估HER3在恶性实体瘤中的预后意义，我们检索了截至2015年12月的PUBMED、EMBASE和CNKI数据库中用英文或中文撰写的相关研究。共纳入15项研究，涉及2964例患者。HER3在恶性实体瘤中的表达率为9.0%-75.1%：乳腺癌中为30.3%-75.1%，结直肠癌中为51.1%-74.5%，胃癌中为13.7%-59.0%，宫颈癌中为54.5%-74.4%。对于恶性实体瘤患者，HER3阳性肿瘤患者的死亡风险高于HER3阴性肿瘤患者（风险比1.60，95%置信区间：1.27 - 2.02，P<0.001）。亚组分析显示，消化系癌或胃癌患者也是如此（风险比1.78，P<0.001；风险比2.18，P<0.001）。相比之下，HER3在结直肠癌或乳腺癌中无预后意义（风险比1.52，P = 0.296；风险比1.23，P = 0.108）。因此，HER3与总体生存率及胃癌患者的不良生存相关。HER3在其他肿瘤中的预后意义尚不确定，值得进一步研究。
